Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2
Authors:
Marlena S. Bannick,
Fei Gao,
Elizabeth R. Brown,
Holly E. Janes
Abstract:
COVID-19 vaccines are highly efficacious at preventing symptomatic infection, severe disease, and death. Most of the evidence that COVID-19 vaccines also reduce transmission of SARS-CoV-2 is based on retrospective, observational studies. Specifically, an increasing number of studies are evaluating vaccine efficacy against the secondary attack rate of SARS-CoV-2 using data available in existing hea…
▽ More
COVID-19 vaccines are highly efficacious at preventing symptomatic infection, severe disease, and death. Most of the evidence that COVID-19 vaccines also reduce transmission of SARS-CoV-2 is based on retrospective, observational studies. Specifically, an increasing number of studies are evaluating vaccine efficacy against the secondary attack rate of SARS-CoV-2 using data available in existing healthcare databases or contact tracing databases. Since these types of databases were designed for clinical diagnosis or management of COVID-19, they are limited in their ability to provide accurate information on infection, infection timing, and transmission events. In this manuscript, we highlight challenges with using existing databases to identify transmission units and confirm potential SARS-CoV-2 transmission events. We discuss the impact of common diagnostic testing strategies including event-prompted and infrequent testing and illustrate their potential biases in estimating vaccine efficacy against the secondary attack rate of SARS-CoV-2. We articulate the need for prospective observational studies of vaccine efficacy against the SARS-CoV-2 SAR, and we provide design and reporting considerations for studies using retrospective databases.
△ Less
Submitted 12 May, 2022;
originally announced June 2022.
Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials
Authors:
Nima S. Hejazi,
Mark J. van der Laan,
Holly E. Janes,
Peter B. Gilbert,
David C. Benkeser
Abstract:
The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success, effective vaccines to prevent many high-burden diseases, including HIV, have been slow to develop. Vaccine development can be aided by the identification of immune response markers that serve as effective surrogates for clinically significant…
▽ More
The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success, effective vaccines to prevent many high-burden diseases, including HIV, have been slow to develop. Vaccine development can be aided by the identification of immune response markers that serve as effective surrogates for clinically significant infection or disease endpoints. However, measuring immune response marker activity is often costly, which has motivated the usage of two-phase sampling for immune response evaluation in clinical trials of preventive vaccines. In such trials, the measurement of immunological markers is performed on a subset of trial participants, where enrollment in this second phase is potentially contingent on the observed study outcome and other participant-level information. We propose nonparametric methodology for efficiently estimating a counterfactual parameter that quantifies the impact of a given immune response marker on the subsequent probability of infection. Along the way, we fill in theoretical gaps pertaining to the asymptotic behavior of nonparametric efficient estimators in the context of two-phase sampling, including a multiple robustness property enjoyed by our estimators. Techniques for constructing confidence intervals and hypothesis tests are presented, and an open source software implementation of the methodology, the txshift R package, is introduced. We illustrate the proposed techniques using data from a recent preventive HIV vaccine efficacy trial.
△ Less
Submitted 3 April, 2020; v1 submitted 30 March, 2020;
originally announced March 2020.
